BMY Earnings Date: Feb 4, 2027 (Estimated) — Bristol-Myers Squibb Company
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is BMY's next earnings date?
Bristol-Myers Squibb Company (BMY) is expected to report Q4 2026 earnings on Thursday, February 4, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.61 on revenue of $12.71B.
How did BMY do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Bristol-Myers Squibb Company posted EPS of $1.35 versus the $1.10 estimate, a beat of 22.7%. Revenue was $13.07B against a $12.72B estimate. The stock's 1-day post-earnings move was +1.4%.
How much does BMY stock move after earnings?
BMY beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
🤖 AI Earnings Analysis
Bristol Myers’ Q3 beat is encouraging: revenue reached $13.1B and adjusted EPS was $1.35, though EPS declined from $1.63 year over year. Full-year guidance stands at $6.75–$7.00 EPS and $49–$50B revenue.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 1.10 | 1.35 | +22.73% | $13.07B | ✅ Beat | +1.35% | — | — |
| 2026-07-30 | Q2 2026 | 1.61 | 2.04 | +26.71% | $12.97B | ✅ Beat | +2.80% | +0.85% | +6.10% |
| 2026-04-30 | Q1 2026 | 1.43 | 1.58 | +10.49% | $11.49B | ✅ Beat | +5.22% | -1.74% | -0.71% |
| 2026-02-05 | Q4 2025 | 1.19 | 1.26 | +5.88% | $12.50B | ✅ Beat | +3.30% | +4.00% | +4.62% |
| 2025-10-30 | Q3 2025 | 1.51 | 1.63 | +7.95% | $12.22B | ✅ Beat | +7.09% | +9.08% | +15.50% |
| 2025-07-31 | Q2 2025 | 1.15 | 1.46 | +26.96% | $12.30B | ✅ Beat | -5.81% | -2.53% | +1.96% |
| 2025-04-24 | Q1 2025 | 1.49 | 1.80 | +20.81% | $11.20B | ✅ Beat | +0.33% | +3.45% | -3.10% |
| 2025-02-06 | Q4 2024 | 1.47 | 1.67 | +13.61% | $12.34B | ✅ Beat | -3.83% | -5.96% | +2.31% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $13.08B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Eliquis | 35.9% | $4.69B | +25.2% | $3.56B | $3.68B | $3.75B | $3.45B |
| Opdivo | 18.2% | $2.37B | -6.2% | $2.27B | $2.56B | $2.53B | $2.69B |
| Orencia | 7.5% | $983.0M | +2.0% | $770.0M | $963.0M | $964.0M | $1.01B |
| Yervoy | 6.1% | $793.0M | +7.3% | $624.0M | $728.0M | $739.0M | $809.0M |
| Reblozyl | 5.7% | $750.0M | +22.0% | $478.0M | $568.0M | $615.0M | $666.0M |
| Other Growth Brands | 5.6% | $731.0M | +42.2% | $403.0M | $470.0M | $514.0M | $537.0M |
| Breyanzi | 4.0% | $526.0M | +46.5% | $263.0M | $344.0M | $359.0M | $392.0M |
By region
Q3 FY26 · $9.48B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 95.7% | $9.07B | +8.9% | $7.87B | $8.52B | $8.33B | $8.56B |
| Other Region | 4.3% | $403.0M | +39.0% | $218.0M | $270.0M | $290.0M | $309.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.